Galapagos NV (GLPG), a bio-pharmaceutical company, Tuesday said it entered into a deal to sell its Jyseleca business to Italian pharma company Alfasigma. As per the terms of the agreement, Michele Manto the Chief Commercial Officer of the company has resigned and will be joining Alfasigma in the same capacity.
BOLOGNA, Italy, November 08, 2023 Alfasigma S.p.A. ("Alfasigma") announced today that it has, through its wholly owned subsidiary Interstellar Acquisition Inc. ("Interstellar"), successfully completed its tender offer to purchase all outstanding shares of common stock of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) ("Intercept"), at a price of USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withholding of taxes.
BOLOGNA, Italy, October 26, 2023 Alfasigma S.p.A. ("Alfasigma") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") with respect to Alfasigma’s proposed acquisition of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) ("Intercept") expired at 11:59 p.m. on October 25, 2023. The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the tender offer. Other customary offer conditions remain to
Intercept Pharmaceuticals’ acquisition by Alfasigma comes three months after the FDA again rejected the biotech’s drug as a treatment for the fatty liver disease NASH. But Intercept still has rare liver disease assets, and Italy-based Alfasigma says acquiring the company will help it expand in gastroenterology and hepatology.